OUR SERVICES

Whether you represent an emerging biotech, a well-established pharmaceutical company, or an academic cancer center aiming to incorporate next-generation molecular testing into standard cancer diagnostics, we are well-equipped to assist you with the following.

Through development of Strategic Expert Groups & Engagement plans we can help you in building a networks of cancer genomics experts which will enable your company to stay at the forefront of research and innovation.

 

Effective Scientific Awareness & Dissemination strategies can amplify your technology’s impact by fostering public engagement, enhancing credibility, influencing policy, and improving patient outcomes.

 

Developing a Strategic plan which considers factors like pricing, customer needs, reimbursement, regulations, and customer access ensures a product’s success in the market.

 

Frequent Voice of Customer (VoC) gathering is vital for understanding customer needs, preferences, and feedback. Integrating VoC ensures
development of patient-centered products, leading to better patient outcomes and effective clinical implementation.

WE CAN SUPPORT PROJECTS IN THE FOLLOWING ONCOLOGY TECHNOLOGIES AND APPLICATIONS

TECHNOLOGICAL EXPERTISE

WHOLE-GENOME SEQUENCING
(WGS)

WGS technology uses next-generations sequencing (NGS) and it allows for the complete sequencing of an individual's genome. It provides a comprehensive molecular view of genetic information within an individual, inherited and acquired mutations which are essential for understanding the genetic basis of cancer, risk-stratification and for identifying right treatment.

WHOLE TRANSCRIPTOME SEQUENCING
(WTS)

WTS provides insights into gene expression patterns, helping identify key genes and gene fusion involved in cancer development and progression. It also provides insight into tumour micro-environment, known to play a key role in patient’s response to immunotherapy.

COMPREHENSIVE GENOMIC PROFILING
(CGP)

CGP involves the analysis of multiple genes using NGS which can identify clinically relevant alterations that can guide personalized cancer treatments.

MINIMAL RESIDUAL DISEASE
(MRD)

MRD monitoring can be used for assessing treatment response, detecting residual cancer cells after therapy and is novel emerging biomarker used for identifying patients at high risk of relapse.

APPLICATIONS

MOLECULAR RISK STRATIFICATION

This is crucial for tailoring treatment plans based on the individual patient's risk profile.

PROGNOSIS AND DIAGNOSTICS

Accurate prognosis and diagnosis are essential for making informed treatment decisions and predicting outcomes.